Associated Papers
Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia.
Hegde PS et al.
Bone Marrow Transplantation, 2025
39424958 (PubMed )
Supplement: 41409_2024_2444_MOESM1_ESM.pdf
Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results.
Olkinuora A et al.
Cancers, 2020
32660107 (PubMed )
Supplement: cancers-12-01853-s001.zip › Supplementary_Files_olkinuora › Table_S2_olkinuora.xlsx › Table_S2
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B et al.
Oncotarget, 2017
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.
Ma HS et al.
Cancer Research, 2014
HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
Syampurnawati M et al.
Leukemia Research, 2007
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Tickenbrock L et al.
Expert Opinion on Emerging Drugs, 2006
Select a paper to view details